Breast Neoplasm Female Clinical Trial
Official title:
A Prospective Study on Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With HR-positive and HER2-negative, Secondary Endocrine-resistant, Locally Advanced or Metastatic Breast Cancer
The management of HR-positive, HER2-negative metastatic breast cancer includes endocrine monotherapy or combination regimens, both with benefit diminishing as resistance develops. Nowadays, various studies have demonstrated that estrogen interacts with many angiogenic pathways and is an important mechanism for resistance leading to the question of whether combination with antiangiogenesis and antiestrogen therapies could be an appropriate therapeutic modality. Anlotinib is a novel multi-target tyrosine kinase inhibitor that effectively inhibit VEGFR, FGFR, PDGFR, c-KIT, c-MET and RET. Previous studies have proven the efficacy of both anlotinib monotherapy and combination regimens in advanced breast cancer. This phase II study aims to preliminarily evaluate the efficacy and safety of anlotinib combined with endocrine therapy.
This study is a prospective, single-arm, open-label, phase II clinical trial. The secondary endocrine-resistant is defined as disease relapse within 12 months after at least 24 months endocrine adjuvant therapy, or disease progress after at least 6 months endocrine salvage therapy. Eligible patients were treated with oral anlotinib plus intramuscular fulvestrant till disease progression or intolerant toxicity. In the part of statistical analysis, 40 patients are required to have a 80% power to detect significant improvement in median progression-free survival from 5.8 (fulvestrant alone) to 10 (fulvestrant combined with anlotinib) months, if tested at a two-sided significance level of α=0.05. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03980626 -
Study on Physical Activity's Relationship With Cancer and Cognition
|
N/A | |
| Completed |
NCT04329819 -
Satisfaction and QUality of Life After Breast REconstruction
|
||
| Recruiting |
NCT03323346 -
Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer
|
Phase 2 | |
| Recruiting |
NCT03900884 -
Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer
|
Phase 1 | |
| Completed |
NCT05042999 -
The Use of Virtual Reality During Breast Ultrasound-Guided Biopsy Procedures
|
N/A | |
| Not yet recruiting |
NCT03662633 -
Diagnosis Value of SEMA4C in Breast Cancer
|
||
| Recruiting |
NCT04456855 -
Locoregional Surgery of the Primary Tumor in de Novo Stage IV Breast Cancer Patients
|
||
| Not yet recruiting |
NCT03629509 -
BEFORE Decision Aid Implementation Study
|
N/A | |
| Completed |
NCT04811378 -
HaemoCerTM Application in Breast Cancer Surgery
|
N/A | |
| Completed |
NCT03198442 -
Breast PET Feasibility
|
N/A | |
| Not yet recruiting |
NCT05577442 -
Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR +/HER2 + Advanced Breast Cancer
|
Phase 2 | |
| Enrolling by invitation |
NCT04047823 -
Temperature and Injury in Radiotherapy Radiation Skin Injury
|
||
| Recruiting |
NCT05452213 -
Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients
|
Phase 4 | |
| Recruiting |
NCT05027321 -
Efficacy of Preparation in Self-Hypnosis by Anchoring Versus Conversational Hypnosis, Used Alone or Combined, in Patients Undergoing Breast Macrobiopsies
|
N/A | |
| Recruiting |
NCT04812652 -
Digitally Distributed Yoga for Women Treated for Breast Cancer
|
N/A | |
| Active, not recruiting |
NCT03425838 -
Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer
|
Phase 3 | |
| Completed |
NCT05473026 -
Grateful Strides Toward Physical Activity and Well-Being for Black Breast Cancer Survivors
|
N/A | |
| Completed |
NCT04509063 -
Investigating Public Enthusiasm for Mammography Screening in Denmark
|
N/A | |
| Recruiting |
NCT05711030 -
Thoracic Paravertebral Block Anesthesia for Breast Cancer Surgery
|
N/A | |
| Suspended |
NCT03271853 -
Thermalogical Analysis of a Cohort of Women and Men Undergoing Mammographic Analysis.
|
N/A |